APP下载

复方苦参注射液联合热灌注化疗治疗恶性腹水的临床研究

2018-08-28孙钦文梁蓝月孙成晖

中国实用医药 2018年15期

孙钦文 梁蓝月 孙成晖

【摘要】 目的 探讨研究复方苦参注射液联合热灌注化疗治疗恶性腹水的临床效果。方法 56例恶性腹水患者, 根据不同的化疗方法分为观察组和对照组, 各28例。对照组采取热灌注化疗, 观察组在此基础上加以复方苦参注射液进行治疗。比较两组患者的临床疗效、不良反应发生率及生活质量评分。结果 观察组疾病控制率(DCR)为78.57%, 高于对照组的50.00%, 差异有统计学意义(P<0.05);观察组不良反应发生率为14.28%, 低于对照组的39.29%, 差异有统计学意义(P<0.05);观察组生活質量评分为(91.63±3.67)分, 明显高于对照组的(82.43±4.82)分, 差异有统计学意义(P<0.05)。结论 针对恶性腹水患者采取复方苦参注射液联合热灌注化疗作为治疗方案, 可在有效改善患者病症控制情况的同时提高其生活质量, 且不良反应少, 安全性高, 值得临床上大力推广。

【关键词】 复方苦参注射液;热灌注化疗;恶性腹水

DOI:10.14163/j.cnki.11-5547/r.2018.15.057

Clinical study of compound Kushen injection combined with thermal perfusion chemotherapy in the treatment of malignant ascites SUN Qin-wen, LIANG Lan-yue, SUN Cheng-hui, et al. Guangdong Yangchun Peoples Hospital, Yangchun 529600, China

【Abstract】 Objective To discuss the clinical effect of compound Kushen injection combined with thermal perfusion chemotherapy in the treatment of malignant ascites. Methods A total of 56 patients with malignant ascites were divided by chemotherapy methods into observation group and control group, with 28 cases in each group. The control group was treated with thermal perfusion chemotherapy, and the observation group was treated with compound Kushen injection on the basis of the control group. The clinical effect and incidence of adverse reactions and quality of life score in two groups was compared. Results The observation group had higher disease control rate (DCR) as 78.57% than 50.00% in the control group, and the difference was statistically significant (P<0.05). The observation group had lower incidence of adverse reactions as 14.28% than 39.29% in the control group, and the difference was statistically significant (P<0.05). The observation group had obviously higher quality of life score as (91.63±3.67) points than (82.43±4.82) points in the control group, and the difference was statistically significant (P<0.05). Conclusion Combination of compound Kushen injection and thermal perfusion chemotherapy helps improve the quality of life of patients with malignant ascites while improving disease control status with less adverse reactions and high safety. It is worthy of clinical promotion.

【Key words】 Compound Kushen injection; Thermal perfusion chemotherapy; Malignant ascites

恶性腹水作为恶性肿瘤携带患者中常见并发症中的一种, 其发病机制是以患者体内肿瘤细胞涉及其腹膜区域从而导致其腹腔内滋生癌细胞, 临床上多是以卵巢癌、胃肠道肿瘤、肝癌、子宫内膜癌等恶性肿瘤作为患者腹腔引发恶性积液的主要病症, 且其具有病情进展快的特点, 若不及时加以控制, 对患者生存质量均会造成严重威胁[1-3]。近年来, 临床上针对此类病症采取体腔局部化疗是控制其病情发展进度的有效措施, 通过注射高浓度药物来直接作用于患者病灶区域, 同时结合温热疗法中的热增敏效应加以辅助, 对提高其整体疗效具有较好的临床价值[4, 5]。本次研究将本院收治的56例恶性腹水患者作研究对象行临床分析, 结果报告如下。

1 资料与方法

1. 1 一般资料 选取2016年4月~2018年3月本院收治的56例消化道肿瘤患者, 按照不同的化疗方法分成观察组和对照组, 各28例。对照组患者男16例, 女12例;年龄33~75岁, 平均年龄(54.39±8.63)岁;疾病类型:6例卵巢癌, 12例胃肠道肿瘤, 10例肝癌。……

登录APP查看全文